EMCURE

Emcure Pharmaceuticals Ltd.

NSE: EMCURE

BSE: 544210

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,783.20-19.5 (-1.08%)

17 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

88.9 / 100

Value Score

35.5 / 100

Price Momentum Score

87.5 / 100

QVM Score

89.5 / 100

Key Metrics

Market Cap

33823.70

P/E (TTM)

36.59

P/B

6.83

P/S (TTM)

3.68

EV/EBITDA

19.64

CAPE (5Y)

51.04

ROE (TTM)

19.68

ROCE (TTM)

22.59

ROA (TTM)

10.36

Avg 3Y ROE

18.79

Earnings 3Y CAGR

20.13

Sales 3Y CAGR

15.42

Sales 5Y CAGR

8.73

Debt/Equity

0.31

Consensus TP

1932.00

Strong Buy %

66.67

Promoter Holding

77.87

Pledged %

0.04

Stock Analysis

Fundamental analysis overview of Emcure Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 87.5 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

87.5 / 100

High and stable ROE

The company reported strong ROE of 19.68% for 12-month ended 31 Mar 2026 and ROE improved marginally by 125 bps from 1 year ago

What is ROE (FY)?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 16.56% for 12-month ended 31 Mar 2026 and the growth was 5.33 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.23

Value 16.56

-82.35114662

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 33.87% for 12-month ended 31 Mar 2026 and the growth was 25.75 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.31 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.08 in the last 1 year

What is Debt to Equity?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 36.59 indicates that the stock is expensive on a standalone basis and is at a 18.49% premium to industry median P/E

What is P/E Ratio?

Median: 30.88

Value 36.59

-44.893379.36

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -0.39% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Not enough data

Low dividend yield

The company has a low dividend yield of 0.17%

What is Dividend yield?

Neutral

Moderate and stable operating margin

The company reported moderate operating margin of 14.92% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 117 bps from 1 year ago

What is Operating profit margin?

Company's earnings are of moderate quality

Earnings quality score of 53.0 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

53.0 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Emcure Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Emcure Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Emcure Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Jul 2014	Jul 2015	Aug 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	15.67	46.28	47.69	47.99	48.00	48.00	48.01	78.08	77.94	77.92	77.91	77.88	77.87	77.87
Indian Promoter	0.00	46.28	47.69	47.99	48.00	48.00	48.01	77.85	77.71	77.69	77.68	77.66	77.65	77.64
Foreign Promoter	15.67	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.23	0.23	0.23	0.23	0.23	0.23
Institutions	0.00	13.09	13.09	13.09	13.09	13.09	13.09	6.87	6.92	6.51	5.70	7.66	9.69	9.46
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.30	3.10	2.73	2.34	3.58	4.83	4.94
FI/Bank/Insurance	0.00	0.00	0.00	13.09	13.09	13.09	13.09	0.49	0.36	0.19	0.24	0.49	0.98	0.87
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
FII	0.00	13.09	13.09	0.00	0.00	0.00	0.00	2.91	3.05	3.06	2.86	3.29	3.59	3.35
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.41	0.52	0.26	0.29	0.29	0.29
Non-Institution	84.33	40.63	39.22	38.92	38.91	38.91	38.90	15.05	15.14	15.57	16.39	14.46	12.44	12.69
Bodies Corporate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.38	0.41	0.71	0.84	0.95	1.17
Others (incl. Retail) No. of shareholders	84.33 0	40.63 0	39.22 0	38.92 0	38.91 0	38.91 0	38.90 0	14.61 1,52,655	14.76 1,43,050	15.16 1,39,298	15.68 1,33,136	13.62 1,25,660	11.49 1,18,374	11.52 1,21,655

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Smallcap 250	0.3%	140 / 249
2	Nifty 500	0.03%	385 / 499
3	Nifty Total Market	0.03%	407 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Emcure Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
ADITYA BIRLA SUN LIFE MUTUAL FUND	25 Jun 2026	buy	₹ 1,817.00	2.61 lac	₹ 47.50 cr
ALPHA ALTERNATIVES EQUITY ABSOLUTE RETURN FUND	25 Jun 2026	buy	₹ 1,817.00	1.38 lac	₹ 25.00 cr
AXIS MUTUAL FUND	25 Jun 2026	buy	₹ 1,817.00	2.75 lac	₹ 50.00 cr
BC INVESTMENTS IV LIMITED	25 Jun 2026	sell	₹ 1,817.00	19.39 lac	₹ 352.40 cr
BNP PARIBAS FINANCIAL MARKETS	25 Jun 2026	buy	₹ 1,817.00	1.38 lac	₹ 25.00 cr
GOLDMAN SACHS INVESTMENTS MAURITIUS I LIMITED	25 Jun 2026	buy	₹ 1,817.00	1.38 lac	₹ 25.00 cr
HDFC STANDARD LIFE INSURANCE COMPANY LTD	25 Jun 2026	buy	₹ 1,817.00	5.57 lac	₹ 101.20 cr
HDFC STANDARD LIFE INSURNACE	25 Jun 2026	buy	₹ 1,817.00	1.58 lac	₹ 28.70 cr
HSBC MUTUAL FUND	25 Jun 2026	buy	₹ 1,817.00	1.38 lac	₹ 25.00 cr
MORGAN STANLEY ASIA SINGAPORE PTE	25 Jun 2026	buy	₹ 1,817.00	1.38 lac	₹ 25.00 cr

Corporate Actions

History of Emcure Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 3/share
Record date: 14th Aug 2025Ex-date: 14th Aug 2025
Announced on: 22nd May 2025

Company Profile

Overview of Emcure Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active...

Key personnel

Mr. Tajuddin Sabir Shaikh

Chief Financial Officer

Dr. Deepak Gondaliya

President - Technical Operations

Mr. Sanjay Rajanikant Mehta

President - Emerging Markets

Mr. Vikas Thapar

President of Corporate Development, Strategy and Finance

Ms. Amruta Amit Yangalwar

Compliance Officer, Company Secretary

Mr. Berjis Minoo DesaiD

Non-Executive Chairman of the Board

Mr. Satish Ramanlal MehtaD

Chief Executive Officer, Managing Director, Executive Director

Dr. Mukund Keshao GurjarD

Chief Scientific Officer, Whole Time Director

View all

Incorporated on

16 Apr 1981

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

10 Jul 2024

Free Float

3,47,12,488

Website

https://www.emcure.com/

Phone no.

+912035070033

Address

Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, PUNE, 411057, India

Frequently Asked Questions

What is the current share price of Emcure Pharmaceuticals Ltd.?

The current share price of Emcure Pharmaceuticals Ltd. is ₹ 1,783.20 as of 17 Jul 2026.

What is the market capitalisation of Emcure Pharmaceuticals Ltd.?

The market capitalisation of Emcure Pharmaceuticals Ltd. stands at ₹ 33,823.70 Cr.

What is the PE ratio of Emcure Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd. is 36.59 as of the latest trailing twelve months data.

What is the ROE and ROCE of Emcure Pharmaceuticals Ltd.?

Emcure Pharmaceuticals Ltd. has a Return on Equity (ROE) of 19.68% and a Return on Capital Employed (ROCE) of 22.59% as per the latest financial reports.

What is the 52-week high and low of Emcure Pharmaceuticals Ltd.?

The 52-week high of Emcure Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Emcure Pharmaceuticals Ltd.?

The dividend yield of Emcure Pharmaceuticals Ltd. is 0.17% based on the current market price.

What is the FII and DII holding in Emcure Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 3.35%, Domestic Institutional Investors (DII) hold 5.81% and retail/public investors hold 11.52% of Emcure Pharmaceuticals Ltd. shares.

What sector does Emcure Pharmaceuticals Ltd. belong to?

Emcure Pharmaceuticals Ltd. operates in the Healthcare sector. 83.33% of analysts have a Buy or Strong Buy rating on Emcure Pharmaceuticals Ltd. with a consensus target price of ₹ 1,932.00, implying 8.34% upside from current levels.

What is the beta of Emcure Pharmaceuticals Ltd.?

The beta of Emcure Pharmaceuticals Ltd. is 0.45, indicating its price volatility relative to the broader market. Over the past 1 year, Emcure Pharmaceuticals Ltd. has delivered an absolute return of 41.73%.

What is the RSI of Emcure Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Emcure Pharmaceuticals Ltd. is 48.50, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Emcure Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Emcure Pharmaceuticals Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Corporate Actions

Company Profile